🇺🇸 FDA
Pipeline program

Rituximab (RTX)

MOR208C204

Phase 3 small_molecule completed

Quick answer

Rituximab (RTX) for Diffuse Large B-cell Lymphoma is a Phase 3 program (small_molecule) at Incyte with 1 ClinicalTrials.gov record(s).

Program details

Company
Incyte
Indication
Diffuse Large B-cell Lymphoma
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials